Yes, because intrusive scanning can disrupt patient care and still miss the attack paths that matter most. The practical priority is passive discovery plus controlled validation of reachability, credential exposure, and pivot paths, so teams can reduce risk without creating clinical downtime.
Why Safe Device Testing Beats Aggressive Scanning in Clinical Environments
Healthcare teams should treat the question as a safety and operations decision, not just a security one. Aggressive scanning can overwhelm fragile medical devices, interrupt clinical workflows, and still fail to tell you which exposed paths actually matter. safe testing focuses on identifying devices, validating exposure, and confirming whether a real path to sensitive systems exists.
The practical distinction is between finding every reachable host and finding the few reachability, credential, and pivot conditions that could lead to meaningful compromise. In healthcare, that second outcome is usually more valuable because it limits disruption while still producing actionable risk evidence.
What Safe Device Testing Actually Looks Like
Safe device testing starts with passive discovery, then moves to controlled validation. That means using inventory data, network observation, and vendor-aware checks before any active probe that could affect availability, reboot behaviour, or real-time telemetry. If a device is life-critical, the default assumption should be that unbounded scanning is too blunt for the environment.
A useful test plan asks three questions: is the device reachable, does it expose credentials or management paths, and can it be used to pivot to something more sensitive? This is where the value lies, because many healthcare exposures are not about the device itself but about weak segmentation, reused credentials, or overly broad administrative paths.
For teams managing fleets with shared imaging, monitoring, or embedded systems, lifecycle visibility matters as much as technical scanning. NHIMG’s NHI Lifecycle Management Guide is useful here because it reinforces the same operational idea: discovery, ownership, rotation, and offboarding are more important than a one-time aggressive sweep.
How to Judge Risk, Reachability, and Blast Radius
Healthcare testing should prioritise controls that answer, "What could actually be reached, used, or crossed?" That usually means validating segmentation, checking whether management interfaces are exposed, and confirming whether credentials or service paths allow lateral movement. If a scan cannot distinguish between harmless visibility and actionable access, it creates noise rather than risk reduction.
Device testing also has a hidden resilience dimension: some assets can tolerate probing, while others cannot be touched without operational coordination. Passive discovery and controlled validation reduce the chance that a security test becomes an availability incident. That is especially important where downtime can delay treatment, interrupt monitoring, or force manual workarounds.
External guidance on operational controls supports this approach. The CIS Controls v8 place clear weight on asset inventory, account management, and vulnerability management, which aligns with testing the exposures that matter before expanding probe depth. For organisations with formal control programmes, the NIST Cybersecurity Framework 2.0 supports the same balance of identify, protect, detect, respond, and recover.
Where healthcare teams are working in regulated environments, the ISO/IEC 27001:2022 Information Security Management standard also maps cleanly to this discipline because it expects organisations to control access, authentication, and operational security in a way that preserves business continuity.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
CIS Controls v8 and NIST CSF 2.0 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| CIS Controls v8 | CIS-1 — Inventory and Control of Enterprise Assets | Safe device testing depends on accurate device discovery and scope control. |
| CIS-6 — Access Control Management | The question centers on credential exposure and pivot paths. | |
| Recommendation — Inventory healthcare assets first so testing targets real devices and excludes fragile out-of-scope systems. Review and restrict device and management-path access before expanding probe activity. | ||
| NIST CSF 2.0 | ID.AM-01 — Physical devices and systems within the organization are inventoried | Passive discovery and controlled validation rely on trustworthy asset visibility. |
| PR.AA-05 — Access permissions and authorizations are managed, incorporating the principles of least privilege and separation of duties | Safe testing should validate exposed credentials and pivot paths tied to authorization boundaries. | |
| Recommendation — Build the test plan from an accurate asset inventory before active validation begins. Validate least-privilege boundaries and remove excessive access paths that make pivoting possible. | ||
| ISO/IEC 27001:2022 | A.5.9 — Inventory of information and other associated assets | Safe testing starts with knowing what devices exist and where they are. |
| A.8.20 — Network security | The decision hinges on segmentation, reachability, and controlled validation of paths. | |
| Recommendation — Maintain an accurate asset inventory before scheduling active testing. Test network reachability and segmentation controls without causing clinical disruption. | ||
Practitioner Guidance
What to prioritise: Start with passive discovery and segmentation validation, then test only the paths that could actually create patient-safety, credential, or pivot risk. If a device is clinically sensitive, treat availability impact as part of the security assessment rather than an acceptable side effect.
What to verify: Confirm that your testing method can show whether a device is reachable, whether credentials or management interfaces are exposed, and whether an attacker could move from that device to a more sensitive target. If it cannot answer those questions, it is too blunt for decision-making.
What good looks like: Teams can identify high-value assets, prove which ones are safely reachable, and document the small number of paths that materially change risk. The result should be better prioritisation, not a larger scan report.
Practitioner takeaway: In healthcare, the best test is the one that reduces uncertainty without creating operational harm, because the goal is to find exploitable paths, not to prove how much the environment can be disrupted.
Related resources from NHI Mgmt Group
- When should security teams prioritise desync testing over generic web scanning?
- When should organisations prioritise safer production scanning over more aggressive testing scans?
- Should security teams prioritise runtime API testing over generic web scanning?
- When should teams prioritise CI/CD hardening over broader secret scanning?
Deepen Your Knowledge
Free weekly newsletter
Subscribe to the NHI & AI Identity Journal
The latest on NHI and Agentic AI security – articles, research, breaches, news and events every week.
Bonus 33% off our NHI Course when you subscribe.
Reviewed and updated by the NHIMG editorial team on October 12, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org